| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Prothrombin |
|---|
| Ligand | BDBM50148994 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEBML_209231 |
|---|
| Ki | 8±n/a nM |
|---|
| Citation |  Lu, T; Markotan, T; Coppo, F; Tomczuk, B; Crysler, C; Eisennagel, S; Spurlino, J; Gremminger, L; Soll, RM; Giardino, EC; Bone, R Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. Bioorg Med Chem Lett14:3727-31 (2004) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Prothrombin |
|---|
| Name: | Prothrombin |
|---|
| Synonyms: | Activation peptide fragment 1 | Activation peptide fragment 2 | Coagulation factor II | F2 | Prothrombin precursor | THRB_HUMAN | Thrombin heavy chain | Thrombin light chain |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 70029.57 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P00734 |
|---|
| Residue: | 622 |
|---|
| Sequence: | MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE
|
|
|
|---|
| BDBM50148994 |
|---|
| n/a |
|---|
| Name | BDBM50148994 |
|---|
| Synonyms: | CHEMBL421096 | Oxyguanidine derivative |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C21H30N4O4 |
|---|
| Mol. Mass. | 402.4873 |
|---|
| SMILES | CCCCN(Cc1ccoc1)C(=O)c1cc(C)cc(OCCCONC(N)=N)c1 |
|---|
| Structure | 
|
|---|
Search and Browse
